**Author details**

Bosco Paes1 , Barry Rodgers-Gray2 and Xavier Carbonell-Estrany3 \*

1 Neonatal Division, Department of Pediatrics, McMaster University, Hamilton, Canada

2 Strategen Limited, Basingstoke, UK

3 Neonatology Service, Hospital Clinic, Institut d'Investigacions Biomediques August Pi Suñer, Barcelona, Spain

\*Address all correspondence to: carbonell@comb.cat

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**39**

*Resolving the Debate on RSV Prophylaxis in Late Preterm Infants*

WHO consultation on respiratory syncytial virus vaccine development

Organization meeting held on 23-24 March 2015. Vaccine. 2016;**34**:190-197. DOI: 10.1016/j.vaccine.2015.05.093

[8] Simoes EAF, Bont L, Manzoni P, Fauroux B, Paes B, Figueras-Aloy J, et al. Past, present and future approaches to the prevention and treatment of respiratory syncytial virus infection in children. Infectious Disease and Therapy. 2018;**7**:87-120. DOI: 10.1007/

[9] Mazur NI, Martinon-Torres F, Baraldi E, Fauroux B, Greenough A, Heikkinen T, et al. Lower respiratory tract infection caused by respiratory syncytial virus: Current management and new therapeutics. The Lancet Respiratory Medicine. 2015;**3**:888-900. DOI: 10.1016/S2213-2600(15)00255-6

[10] The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;**102**:531-537

[11] Notario G, Vo P, Gooch K, Deaton R, Wu X, Harris B. Respiratory syncytial

bronchopulmonary dysplasia: Subgroup efficacy analysis of the IMpact-RS V trial by gestational age group. Pediatric Health, Medicine and Therapeutics. 2014;**5**:43-48. DOI: 10.2147/PHMT.

[12] Robinson JL, Le Saux N, Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Preventing hospitalizations for respiratory syncytial virus infection.

Paediatrics & Child Health. 2015;**20**:321-333. DOI: 10.1093/

virus-related hospitalization in premature infants without

S59572

pch/20.6.321

report from a World Health

s40121-018-0188-z

*DOI: http://dx.doi.org/10.5772/intechopen.85073*

[1] Shi T, McAllister DA, O'Brien KL, Simoes EAF, Madhi SA, Gessner BD, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. Lancet. 2017;**390**:946-958. DOI: 10.1016/

[2] Hasegawa K, Tsugawa Y, Brown DF, Mansbach JM, Camargo CA Jr. Trends in bronchiolitis hospitalizations in the United States, 2000-2009. Pediatrics.

[3] Figueras-Aloy J, Manzoni P, Paes B, Simões EA, Bont L, Checchia PA, et al. Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among preterm infants without chronic lung disease or congenital heart disease. Infectious Disease and Therapy. 2016;**5**:417-452. DOI: 10.1007/

[4] Resch B. Respiratory syncytial virus infection in high-risk infants—An update on palivizumab prophylaxis. Open Microbiology Journal. 2014;**11**: 71-77. DOI: 10.2174/1874285801408010071

[5] World Health Organization. Born too soon: The global action report on preterm birth [Internet]. 2012. Available from: http://apps.who.int/iris/

[6] Martin JA, Hamilton BE, Osterman MJK, Driscoll AK, Mathews TJ. Births: Final data for 2015. National Vital Statistics

[7] Modjarrad K, Giersing B, Kaslow DC, Smith PG, Moorthy VS, WHO RSV vaccine consultation expert group.

bitstream/10665/44864/1/ 9789241503433\_eng.pdf?ua=1 [Accessed: 2019-01-24]

Reports. 2017;**66**:1-69

S0140-6736(17)30938-8

2013;**132**:28-36. DOI: 10.1542/

peds.2012-3877

s40121-016-0130-1

**References**

*Resolving the Debate on RSV Prophylaxis in Late Preterm Infants DOI: http://dx.doi.org/10.5772/intechopen.85073*
